Clinical Trial Update: A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lapatinib in combination with everolimus for advanced triple-negative breast cancer was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Everolimus (everolimus)
• Lapatinib (Lapatinib)

Snippet

Sponsor: Emory University | Conditions: Breast Neoplasms, Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-09-10